Concerta shortage extended to December 2026 — what ADHD patients need to know

What happened

The TGA has extended the shortage notification for Concerta modified-release tablets to 31 December 2026. All strengths — 18mg, 27mg, 36mg, and 54mg — remain subject to intermittent and variable supply throughout the year.

Concerta (methylphenidate hydrochloride modified-release) is one of Australia’s most-prescribed ADHD medications. This extension is not a regulatory withdrawal. The medicine remains on the Australian Register of Therapeutic Goods and continues to be the preferred option for many patients — there is simply not enough of it consistently available in the supply chain.

If you or someone in your household is managing ADHD on methylphenidate and has been turned away at the pharmacy, you are not alone, and this is going to continue for the rest of 2026.

Why this is happening

The methylphenidate shortage has a structural cause, not a clinical one. Manufacturing issues — primarily difficulties sourcing active pharmaceutical ingredients and US production quota constraints — have limited global supply. At the same time, Australian demand has surged: according to newsGP reporting, prescriptions filled for methylphenidate increased by 88% over an 18-month period to mid-2025. That combination — constrained supply, sharply rising demand — is why the shortage has persisted for well over a year, and why it is now confirmed to continue to the end of this year.

The prescription increase reflects a real clinical phenomenon: adult ADHD — and late diagnosis in women in particular — has become increasingly recognised in Australian clinical practice. A generation of women who were missed in childhood assessments are now receiving diagnoses, often in their 30s, 40s, and 50s. For many, medication is a central part of managing ADHD in daily life. That makes the shortage genuinely disruptive, not a minor inconvenience.

The both-and

Two things are true at once here, and both are worth naming.

The first: the methylphenidate shortage is a supply-chain problem, and the right clinical response is finding a workable medication option — whether that is an alternative methylphenidate formulation, a different stimulant class, or a non-stimulant option where appropriate. newsGP has consistently reported that alternatives exist and that GPs are well positioned to navigate the switch with their patients.

The second: switching ADHD medication is not a seamless administrative step. Moving from one stimulant to another — or from methylphenidate to lisdexamfetamine — requires re-titration. The dose that worked on one medication does not translate directly to another. Starting a new medication means a period of finding the right dose again, which can involve temporary disruption to work, study, and daily function before things settle.

Reporting from The Conversation has noted that abrupt stopping is the outcome most worth avoiding — people who stop methylphenidate suddenly due to lack of supply often experience a sharp return of symptoms before an alternative is sorted. That gap is manageable with good GP coordination, but is genuinely disruptive without it.

What options exist right now

The TGA has approved the supply of the Swiss-registered version of Concerta as a bridging measure. Ask your pharmacist specifically whether this is available — it may not appear in standard dispensing systems in the same way as the Australian-registered product, but pharmacies with access to it will know.

Other methylphenidate formulations — Ritalin LA and Methylphenidate-Teva XR — have had their own supply disruptions, but availability varies by pharmacy and region. Ringing around to multiple pharmacies is genuinely useful and often finds stock that a single call would miss.

If methylphenidate in any form is unavailable, the most common stimulant alternative used in this context is lisdexamfetamine (Elvanse). It is in a different chemical class, requires its own dose-finding process, and is not the right choice for everyone — but for many adults on methylphenidate, the transition is manageable with GP guidance.

Non-stimulant options — atomoxetine, guanfacine — exist but are generally reserved for situations where stimulants are not tolerated or are contraindicated. That is a specialist-level conversation and not a first-line step to attempt without medical input.

2 cents

If your supply is disrupted, contacting your prescribing GP before stopping is strongly recommended. Even a short gap without coordination can mean a significant return of symptoms, and your GP can help you bridge to an alternative while pharmacy stock is sorted.

If you have been managing adequately on Concerta and the disruption is intermittent, some patients find that contacting multiple pharmacies — or using a pharmacy with strong ordering capacity — can secure stock even during shortage periods.

The shortage is confirmed through December 2026. Building a practical contingency plan with your GP now, rather than managing crisis to crisis through each script cycle, is worth the appointment.

Verdict

Verdict: yes — worth knowing about.

The Concerta shortage has been running long enough that many patients have already adapted. For those who have not, or who are newly prescribed, the extension to December 2026 means this is not resolving soon. Knowing your options — and having that conversation with your GP proactively — is the most practical thing you can do this week.

---

Sources cited

1. TGA — Update: methylphenidate products shortage dates extended
2. TGA — About the shortage of methylphenidate hydrochloride products
3. newsGP — GPs advised of extension to ADHD medication shortage
4. The Conversation — Can’t fill your ADHD script? Here’s why, and what to do